Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump

MT Newswires Live

Feb 14, 2025

Pliant Therapeutics' (PLRX) shares rose by than 32% in recent Thursday trading after the company said it has begun assembling an external expert panel to evaluate unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.

This move comes after the trial's independent Data Safety Monitoring Board recommended pausing enrollment and dosing, the company said, adding that it has been unable to identify the rationale behind the DSMB's recommendation after reviewing blinded data.

The panel, consisting of pulmonary disease and biostatistics experts, will offer an independent recommendation and later collaborate with an expanded DSMB to reach a consensus on BEACON-IPF. The process is expected to conclude in 2 to 4 weeks.

Following the DSMB's recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF trial while remaining blinded to preserve data integrity of the BEACON-IPF 2b and its potential as a registrational study, the company said.

Price: 3.48, Change: +0.76, Percent Change: +27.94

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2511527645"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511527645\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2511527645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-14 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511527645","market":"sg","top_or_hot":-1,"title":"Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump","media":"MT Newswires Live","content":"<html><body><p> Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (PLRX) shares rose by than 32% in recent Thursday trading after the company said it has begun assembling an external expert panel to evaluate unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.</p><p>This move comes after the trial's independent Data Safety Monitoring Board recommended pausing enrollment and dosing, the company said, adding that it has been unable to identify the rationale behind the DSMB's recommendation after reviewing blinded data.</p><p>The panel, consisting of pulmonary disease and biostatistics experts, will offer an independent recommendation and later collaborate with an expanded DSMB to reach a consensus on BEACON-IPF. The process is expected to conclude in 2 to 4 weeks.</p><p>Following the DSMB's recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF trial while remaining blinded to preserve data integrity of the BEACON-IPF 2b and its potential as a registrational study, the company said.</p><p>Price: 3.48, Change: +0.76, Percent Change: +27.94</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-14 00:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (PLRX) shares rose by than 32% in recent Thursday trading after the company said it has begun assembling an external expert panel to evaluate unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.</p><p>This move comes after the trial's independent Data Safety Monitoring Board recommended pausing enrollment and dosing, the company said, adding that it has been unable to identify the rationale behind the DSMB's recommendation after reviewing blinded data.</p><p>The panel, consisting of pulmonary disease and biostatistics experts, will offer an independent recommendation and later collaborate with an expanded DSMB to reach a consensus on BEACON-IPF. The process is expected to conclude in 2 to 4 weeks.</p><p>Following the DSMB's recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF trial while remaining blinded to preserve data integrity of the BEACON-IPF 2b and its potential as a registrational study, the company said.</p><p>Price: 3.48, Change: +0.76, Percent Change: +27.94</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2511527645","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511527645","pubTimestamp":1739463356,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pliant Therapeutics'  shares rose by than 32% in recent Thursday trading after the company said it has begun assembling an external expert panel to evaluate unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.This move comes after the trial's independent Data Safety Monitoring Board recommended pausing enrollment and dosing, the company said, adding that it has been unable to identify the rationale behind the DSMB's recommendation after reviewing blinded data.The panel, consisting of pulmonary disease and biostatistics experts, will offer an independent recommendation and later collaborate with an expanded DSMB to reach a consensus on BEACON-IPF. The process is expected to conclude in 2 to 4 weeks.Following the DSMB's recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF trial while remaining blinded to preserve data integrity of the BEACON-IPF 2b and its potential as a registrational study,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PLRX":"Pliant Therapeutics, Inc.","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Pliant Therapeutics将组建专家小组审查BEACON-IPF试验数据；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PLRX":0.9},"content_text":"Pliant Therapeutics' (PLRX) shares rose by than 32% in recent Thursday trading after the company said it has begun assembling an external expert panel to evaluate unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.This move comes after the trial's independent Data Safety Monitoring Board recommended pausing enrollment and dosing, the company said, adding that it has been unable to identify the rationale behind the DSMB's recommendation after reviewing blinded data.The panel, consisting of pulmonary disease and biostatistics experts, will offer an independent recommendation and later collaborate with an expanded DSMB to reach a consensus on BEACON-IPF. The process is expected to conclude in 2 to 4 weeks.Following the DSMB's recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF trial while remaining blinded to preserve data integrity of the BEACON-IPF 2b and its potential as a registrational study, the company said.Price: 3.48, Change: +0.76, Percent Change: +27.94","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}